Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis.

Diabetologia - 1 Sept 2015

Bonnefond Amélie, Yengo Loïc, Le May Cédric, Fumeron Fréderic, Marre Michel, Balkau Beverley, Charpentier Guillaume, Franc Sylvia, Froguel Philippe, Cariou Bertrand

Abstract excerpt

AIMS/HYPOTHESIS: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a critical regulator of cholesterol homeostasis. PCSK9 inhibitors are being actively developed to lower LDL-cholesterol levels. However, there are conflicting data regarding the consequences of Pcsk9 deficiency on glucose homeostasis in mouse models. Here, we analysed in humans the association between the PCSK9 p.R46L loss-of-function (LOF)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Glucose
Share to Cholesterol

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to France

Share to Homeostasis

Share to Proprotein Convertase 9

Share to Proprotein Convertases

Share to Regression Analysis

Share to Serine Endopeptidases

Source

Identifiers

PMID: 26049403
DOI: 10.1007/s00125-015-3659-8

Genes

PCSK9

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis.PMID 26049403Read ↗

Effect of the PCSK9 R46L genetic variant on plasma insulin and glucose levels, risk of diabetes mellitus and cardiovascular disease: A meta-analysis.Semantic proximity Read ↗

Regional distribution and metabolic effect of PCSK9 insLEU and R46L gene mutations and apoE genotype.Semantic proximity Read ↗

PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans.Semantic proximity Read ↗

Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants.Semantic proximity Read ↗

Loss-of-function mutation of PCSK9 as a protective factor in the clinical expression of familial hypercholesterolemiaSemantic proximity Read ↗

Mutation S462P in the PCSK9 gene reduces secretion of mutant PCSK9 without affecting the autocatalytic cleavage.Semantic proximity Read ↗

Functional and clinical relevance of novel and known PCSK1 variants for childhood obesity and glucose metabolism.Semantic proximity Read ↗

Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes/diabetes risk.Semantic proximity Read ↗

Common and low-frequency genetic variants in the PCSK9 locus influence circulating PCSK9 levels.Semantic proximity Read ↗

PCSK9 R46L, Lower LDL, and Cardiovascular Disease Risk in Familial HypercholesterolemiaSemantic proximity Read ↗

PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial HypobetalipoproteinemiaSemantic proximity Read ↗

Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.